Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + onalespib
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of erlotinib, an EGFR tyrosine kinase inhibitor, and onalespib, a novel heat shock protein 90 inhibitor (HSP90i). This combination was investigated for the treatment of EGFR-mutant non-small cell lung cancer, particularly in patients with epidermal growth factor receptor exon 20 insertion (EGFRex20ins).
02
Targets
EGFR (Epidermal growth factor receptor)HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on erlotinib + onalespib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + onalespib.